Engineered immune cells take aim at Hard-to-Treat leukemia
NCT ID NCT06071624
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called CD4CAR T cells for people with chronic myelomonocytic leukemia (CMML) that has come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. The main goals are to find a safe dose and see if it can reduce cancer in the bone marrow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD4CAR T cells (immune cells engineered to target CD4-positive cells)
What this could lead to
If successful, this could point toward a new treatment option for people with CMML that has not responded to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so safety and dosing are still being figured out. It may not work or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Albert Einstein Health Network
NOT_YET_RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida 33136
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact